Evidence map›Paper›PMID 37171519›Full record

ArticleEuropean journal of pediatrics2023

Clinical usefulness of anti-nuclear antibody in childhood: real-world experience at a tertiary care center : Usefulness of ANA in pediatric autoimmune diseases.

Nihal Şahin, Ayşenur Paç Kısaarslan, Sümeyra Özdemir Çiçek, Ayşe Seda Pınarbaşı, Neslihan Günay, Sibel Yel, İsmail Dursun, Muammer Hakan Poyrazoğlu, Ruhan Düşünsel

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. [Clincial Diagnostic Performance of EULAR/ACR-2019, SLICC-2012, and ACR-1997 Classification Criteria for Childhood Systemic Lupus Erythematosus].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Nihal ŞahinDepartment of Pediatrics, Division of Pediatric Rheumatology, Kocaeli University, Kocaeli University Research and Application Hospital Umuttepe, Campus 41380, İzmit, Kocaeli, Turkey. nihal_sahin41@hotmail.com.ORCID http://orcid.org/0000-0002-2122-6952
Ayşenur Paç KısaarslanDepartment of Pediatrics, Division of Pediatric Rheumatology, Erciyes University, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-1800-9922
Sümeyra Özdemir ÇiçekDepartment of Pediatric Rheumatology, Kayseri City Hospital, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-3290-4413
Ayşe Seda PınarbaşıDepartment of Pediatric Nephrology, Diyarbakır Pediatric Hospital, Diyarbakır, Turkey.ORCID http://orcid.org/0000-0002-2443-4378
Neslihan GünayDepartment of Pediatric Nephrology, Kayseri City Hospital, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-0995-8501
Sibel YelDepartment of Pediatrics, Division of Pediatric Nephrology, Erciyes University, Kayseri, Turkey.ORCID http://orcid.org/0000-0001-5707-1633
İsmail DursunDepartment of Pediatrics, Division of Pediatric Nephrology, Erciyes University, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-0191-4344
Muammer Hakan PoyrazoğluDepartment of Pediatrics, Division of Pediatric Nephrology and Division of Pediatric Rheumatology, Erciyes University, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-5142-8432
Ruhan DüşünselDepartment of Pediatrics, Division of Pediatric Nephrology and Rheumatology, Yeditepe Univesity, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-0599-7199
Erciyes University · TRKayseri Eğitim ve Araştırma Hastanesi · TRDiyarbakır Askeri Hastanesi · TRKocaeli Üniversitesi · TRYeditepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the reasons for requesting anti-nuclear antibody (ANA) analysis in clinical practice at a tertiary center and the performance of ANA in pediatric autoimmune diseases. Patients under 18 years of age who underwent ANA testing for various symptoms between 2013 and 2017 were included. We retrieved data from medical records, including demographic and clinical characteristics, diagnoses, ANA results, titers, and staining patterns. The performance assessment tools were calculated according to the ANA titer for autoimmune diseases. Risk factors for autoimmune diseases in ANA-positive patients were evaluated using logistic regression analysis. Changes in ANA titer and seroconversion were evaluated using repeated ANA analyses. A total of 3812 patients underwent ANA. Medical records of 3320 patients were obtained. The rate of ANA positivity was 27.4%. ANA was requested most frequently because of musculoskeletal findings in 1355 patients (40.8%). Juvenile idiopathic arthritis (n = 174, 20.2%) was the most common diagnosis in ANA-positive patients, followed by systemic lupus erythematosus (n = 52, 6%). For autoimmune diseases, a titer of ≥ 1:100, a sensitivity of 40.1%, and a specificity of 77.1% were observed. At a titer ≥ 1:1000, the sensitivity and specificity were 24.1% and 89%, respectively. Homogeneous staining was an additional risk factor for autoimmune diseases in ANA-positive patients by multivariate logistic regression analysis (OR [95% CI]: 4.562 [3.076-6.766], p < 0.001).    Conclusion: Our results revealed that the performance of the ANA test in diagnosing autoimmune diseases in pediatric clinical practice was poor. Therefore, clinical findings should be carefully evaluated before ANA testing is performed. What is Known: • ANA can be detected in systemic autoimmune rheumatic diseases. • The diagnostic role of ANA is controversial, especially in childhood. What is New: • One in four patients who requested the ANA test had an autoimmune disease. • Less than half of patients with an autoimmune disease had ANA positivity.

Indexed as

Arthritis, JuvenileAutoimmune DiseasesLupus Erythematosus, SystemicAdolescentAntibodies, AntinuclearChildHumansSensitivity and SpecificityTertiary Care CentersAntibodies, AntinuclearAnti-nuclear antibodyAutoimmune diseaseDiagnostic markerPediatricRheumatology

Identifiers

PMID37171519
OpenAlexW4376226317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.